Matrifen® for Therapy of Severe Chronic Pain® (Matrix LQ)

Nycomed

Status: Completed

Conditions: Severe Chronic Pain

Treatments: Drug: Fentanyl

Study type: Observational

Funder types: Industry

Identifiers

NCT00699335

Matrix LQ, FT-1300-028

Details and patient eligibility

About

The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).

Enrollment: 5,308 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main inclusion criteria:

• Outpatients with severe, chronic pain

Main exclusion criteria:

• Hypersensitivity to fentanyl
• Co-administration of monoamineoxidase-inhibitors
• Pregnancy
• Respiratory depression
• Chronic obstructive pulmonary disease (COPD)
• Drug abuse
• Impairment of CNS functions
• Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)